Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
FDA tightens up digital health oversight
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Astra shakes things up with Covid-19 pricing disclosure
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Market says meh to presidential drug pricing orders
There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
